After listening to the enterprise AI specialist's latest earnings call, I have some concerns over where the company is headed ...

C3.ai's growth is fairly modest given its size and the strength of the demand environment. Read why I remain neutral on AI ...

Investors should always rely on their own analysis, not just management talk and projections, when deciding whether to buy a ...

Cannabinoid-focused biopharmaceutical company C3 Pharmaceuticals announces a planned listing on the Canadian Securities ...

September saw cobalt spot prices slightly lower and LME inventory levels unchanged. Read more to see the full update for ...

The new iteration of C3 Pharmaceuticals, Inc. announced that it executed a tailored Share Subscription Agreement (SSA) with ...

Shares of C3.ai Inc. AI sank 0.26% to $23.27 Wednesday, on what proved to be an all-around grim trading session for the stock ...

This was the stock's fourth consecutive day of gains.

Enterprises and institutions are rushing to develop an AI strategy, which will be a tailwind for these two AI stocks.

C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

Executives are fighting back against a federal court decision that banned them from the securities industry and ordered them ...

We recently published a list of 10 AI News and Analyst Ratings You Should Not Miss. Since C3.ai Inc (NYSE:AI) ranks 10th on ...